RAD001 (everolimus) in combination with weekly paclitaxel and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab: a multicenter phase I clinical trial.
Keyword(s):
Phase I
◽
2010 ◽
Vol 28
(15_suppl)
◽
pp. 1013-1013
◽
2019 ◽
Vol 25
(17)
◽
pp. 5212-5220
◽